Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Opioid addiction is a chronic and complex disease characterized by relapse and remission. In the past decade, the opioid epidemic or opioid crisis in the United States has raised public awareness. Methadone, buprenorphine, and naloxone have proven their effectiveness in treating addicted individuals, and each of them has different effects on different opioid receptors. Classic and molecular genetic research has provided valuable information and revealed the possible mechanism of individual differences in vulnerability for opioid addiction. The polygenic risk score based on the results of a genome-wide association study (GWAS) may be a promising tool to evaluate the association between phenotypes and genetic markers across the entire genome. A novel gene editing approach, clustered, regularly-interspaced short palindromic repeats (CRISPR), has been widely used in basic research and potentially applied to human therapeutics such as mental illness; many applications against addiction based on CRISPR are currently under research, and some are successful in animal studies. In this article, we summarized the biological mechanisms of opioid addiction and medical treatments, and we reviewed articles about the genetics of opioid addiction, the promising approach to predict the risk of opioid addiction, and a novel gene editing approach. Further research on medical treatments based on individual vulnerability is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821 · cited 1×
“The first successful polygenic score analysis in/within a GWAS was applied to schizophrenia and bipolar disorder [98].”
BackgroundProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622 · cited 1×
“Opioid addiction is a chronic mental illness that causes the addicted individuals to experience many relapses and remissions throughout their life, and they suffer from many uncomfortable symptoms, including tolerance development and withdrawal [1,2].”
BackgroundGrant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556 · cited 1×
“Compared to smoking and alcohol consumption, opioid addiction is less common; however, it has imposed a heavy burden on both healthcare systems and the criminal justice system [3,4].”
BackgroundPower and predictive accuracy of polygenic risk scores
Dudbridge, F. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003348 · Cited by 1,509 · cited 1×
“A polygenic risk score is then constructed in an independent sample as a weighted sum scores trait-associated alleles for each subject, for different subsets of top ranking markers [97].”
BackgroundThe brain on drugs: from reward to addiction
Volkow, N. D., & Morales, M. (2015) · Cell · doi:10.1016/j.cell.2015.07.046 · Cited by 1,306
CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
The neurobiology of anhedonia and other reward-related deficits
Der-Avakian, A., & Markou, A. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.005 · Cited by 1,130 · cited 1×
“As opioid tolerance develops, compulsive seeking for more opiates and uncontrolled intake emerges; as a result, the homeostasis of brain reward circuits and the ability to maintain fair social functioning becomes compromised [42].”
BackgroundKreek, M. J., Nielsen, D. A., Butelman, E. R., & LaForge, K. S. (2005) · Nature Neuroscience · doi:10.1038/nn1583 · Cited by 1,024
Reward Processing by the Opioid System in the Brain
Le Merrer, J., Becker, J. A. J., Befort, K., & Kieffer, B. L. (2009) · Physiological Reviews · doi:10.1152/physrev.00005.2009 · Cited by 1,013
p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0050-6 · Cited by 978
Familial Transmission of Substance Use Disorders
Merikangas, K. R., Stolar, M., Stevens, D. E., Goulet, J., Preisig, M. A., Fenton, B., Zhang, H., O'Malley, S. S., & Rounsaville, B. J. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.11.973 · Cited by 783 · cited 1×
“reported an eight-fold increase in the odds of drug disorders among the relatives of probands with drug disorders, with the greatest odds ratio observed for addiction to the same substance [78].”
BackgroundClinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773 · cited 1×
“respiratory depression; thus, it is safer than methadone and adequate to alleviate opioid withdrawal symptoms [59].”
BackgroundWaldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073940 · Cited by 740
Tsuang, M. T., Lyons, M. J., Meyer, J. M., Doyle, T., Eisen, S. A., Goldberg, J., True, W., Lin, N., Toomey, R., & Eaves, L. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.11.967 · Cited by 710 · cited 1×
“4, indicating there could be unique genetic factors affecting opioid abuse [67].”
BackgroundKendler, K. S., Jacobson, K. C., Prescott, C. A., & Neale, M. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.687 · Cited by 693
Societal costs of prescription opioid abuse, dependence, and misuse in the United States
Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., Cleveland, J. M., & Roland, C. L. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01075.x · Cited by 644
Incidence, reversal, and prevention of opioid-induced respiratory depression
Dahan, A., Aarts, L., & Smith, T. W. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181c38c25 · Cited by 634 · cited 1×
“Addicted individuals receiving MMT and consuming alcohol and/or sedatives at the same time are at high risk of respiratory depression [56].”
BackgroundFudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577
The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors
Bruchas, M. R., Land, B. B., & Chavkin, C. (2010) · Brain Research · doi:10.1016/j.brainres.2009.08.062 · Cited by 544 · cited 1×
“Prolonged exposure to drugs of abuse can change the brain reward circuits and enhance the KOR function through the hypothalamic–pituitary–adrenal axis, promoting opioid addiction relapse [46,47]; furthermore, stress due to prolonged exposure to drugs can also produce a dysphoric feeling.”
BackgroundWeiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540 · cited 1×
“Buprenorphine, in combination with naloxone is used commonly to treat opioid addiction in the United States, and the addicted individuals are less likely to inject it due to severe opioid withdrawal [60].”
BackgroundBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Genomewide Association Studies: History, Rationale, and Prospects for Psychiatric Disorders
Psychiatric GWAS Consortium Coordinating Committee (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08091354 · Cited by 450
Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis
Diabetes Genetics Replication and Meta-analysis Consortium, Stahl, E. A., Myocardial Infarction Genetics Consortium, Wegmann, D., Trynka, G., Gutierrez-Achury, J., Do, R., Voight, B. F., Kraft, P., Chen, R., et al. (2012) · Nature Genetics · doi:10.1038/ng.2232 · Cited by 388
CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool
Brokowski, C., & Adli, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.044 · Cited by 320
Profile of Executive and Memory Function Associated with Amphetamine and Opiate Dependence
Ersche, K. D., Clark, L., London, M., Robbins, T. W., & Sahakian, B. J. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300889 · Cited by 311 · cited 1×
“Intellectual functional impairment—specifically, cognitive impairment and poor judgement—can be found in addicts who regularly use opioid and amphetamines [24].”
BackgroundThe Opioid Epidemic: Crisis and Solutions
Skolnick, P. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052534 · Cited by 307
Cornelis, M. C., Monda, K. L., Yu, K., Paynter, N., Azzato, E. M., Bennett, S. N., Berndt, S. I., Boerwinkle, E., Chanock, S., Chatterjee, N., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002033 · Cited by 228
Are adolescents more vulnerable to drug addiction than adults? Evidence from animal models
Schramm-Sapyta, N. L., Walker, Q. D., Caster, J. M., Levin, E. D., & Kuhn, C. M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1585-5 · Cited by 215
Distinct opioid circuits determine the palatability and the desirability of rewarding events
Wassum, K. M., Ostlund, S. B., Maidment, N. T., & Balleine, B. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905874106 · Cited by 182
Troisi, A., Frazzetto, G., Carola, V., Di Lorenzo, G., Coviello, M., D'Amato, F. R., Moles, A., Siracusano, A., & Gross, C. (2011) · Social Neuroscience · doi:10.1080/17470919.2010.482786 · Cited by 118 · cited 1×
“A common polymorphism (A118G) in the MOR gene (OPRM1) is associated with social rejection and social hedonism in the study of human neural sensitivity [40], and recent mice studies suggest that the MOR is also associated with social attachment and anhedonia [41].”
BackgroundPolygenic risk scores for schizophrenia and bipolar disorder associate with addiction
Reginsson, G. W., Ingason, A., Euesden, J., Bjornsdottir, G., Olafsson, S., Sigurdsson, E., Oskarsson, H., Tyrfingsson, T., Runarsdottir, V., Hansdottir, I., et al. (2018) · Addiction Biology · doi:10.1111/adb.12496 · Cited by 112 · cited 1×
“The polygenic risk scores analysis has been applied to psychiatric disorders such as schizophrenia and bipolar disorder, and the findings have supported the idea that schizophrenia and bipolar disorder are complex diseases [99,120].”
BackgroundMedications for substance use disorders
Douaihy, A. B., Kelly, T. M., & Sullivan, C. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.759031 · Cited by 93
Cited by
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
“Pharmacological treatments against AUD, opioid use disorder (OUD) and tobacco use disorder are available (see Table 1) (European Monitoring Centre for Drugs and Drug Addiction, 2012; Kampman, 2019; Kranzler & Soyka, 2018; Lee et al., 2018; Prochaska & Benowitz, 2016; Wang et al., 2019).”
BackgroundTomitaka, A., Vashist, A., Kolishetti, N., & Nair, M. (2023) · Nanoscale Advances · doi:10.1039/d3na00180f · Cited by 45
Blum, K., Steinberg, B., Gondré-Lewis, M. C., Baron, D., Modestino, E. J., Badgaiyan, R. D., Downs, B. W., Bagchi, D., Brewer, R., McLaughlin, T., et al. (2021) · Psychology Research and Behavior Management · doi:10.2147/prbm.s292958 · Cited by 20
Liu, J., Di, J., Zhang, Y., & Xing, E. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00828-5 · Cited by 10
Metadata
- Authors
- Wang, S.-C., Chen, Y.-C., Lee, C.-H., & Cheng, C.-M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-09-02
- Volume
- 20
- Issue
- 17
- Pages
- 4294
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2971173212
- Cited by
- 148
- References
- 34
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.